The move has come just a few weeks after CARGO's plans were thrown into disarray when safety concerns scuppered a mid-stage trial of its lead CAR-T firicabtagene autoleucel (CRG-022), causing the ...

Its investment in CAR-T drugs is part of that ambitious push, and 2017 is set to be a decisive year for Novartis and main rival, Kite Pharma, who lead this hugely promising but risky field.